Dune Medical Devices

Company Overview

Snapshot

Founded in January 2002 by Dan Hashimshony, Dune Medical Devices operated with 11–50 employees. The company raised a total of $53.8 million across 6 funding rounds from 5 investors. In April 2020, Dune Medical Devices was acquired by Dilon Technologies.

Business overview

Dune Medical Devices developed tissue characterization technology for diagnostic and therapeutic applications, enabling real-time cancer detection for surgeons and radiologists. Its core product, the MarginProbe System, utilizes a Fringe Field Sensor to assess excised tissue margins in the operating room. The company was also developing a smart biopsy system for breast tissue, expanding its surgical oncology portfolio. Dune Medical Devices operated within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices, serving the healthcare provider market.

Strategic signal

In April 2020, Dune Medical Devices was acquired by Dilon Technologies. This acquisition highlights the strategic value of Dune Medical's real-time cancer detection technology, particularly its MarginProbe system, and signals a consolidation within the medical device market focused on improving surgical outcomes for cancer patients.

Company Intelligence Q&A

What is Dune Medical Devices' primary technology?

Dune Medical Devices developed tissue characterization technology, notably the MarginProbe System, which uses a Fringe Field Sensor to provide real-time cancer detection by assessing the margins of excised tissue during surgery.

When was Dune Medical Devices acquired?

Dune Medical Devices was acquired by Dilon Technologies in April 2020.

Which investors participated in Dune Medical Devices' July 2017 funding round?

In July 2017, Dune Medical Devices received funding from Canepa Healthcare, The Kraft Group, and ATON Partners.

What was the focus of Dune Medical Devices' product development in March 2019?

In March 2019, Dune Medical Devices was developing a smart biopsy device designed to diagnose breast cancer using miniature radiofrequency sensors, aiming to expand its surgical oncology portfolio.

What significant clinical data was highlighted for MarginProbe in February 2019?

In February 2019, clinical data supported MarginProbe as the only FDA-approved device for identifying positive margins during breast conservation surgery, demonstrating its effectiveness in reducing re-excision rates.